Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)
Funding Amount
Not stated
Deadline
Forecast — dates not yet posted
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Tribal organizations
- Public colleges & universities
- Private colleges & universities
- Tribal governments
- Small businesses
- State governments
- Public & Indian housing authorities
- School districts
Overview
The National Center for Advancing Translational Science (NCATS) seeks to advance its mission by advancing research on extracellular vesicles (EVs) and their use as therapeutics in the field of regenerative medicine. The main objective of this program, Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe) , is to support the translation of EV-based therapeutics in regenerative medicine. EVs, like exosomes and microvesicles, are crucial mediators of intercellular communication, carrying diverse cargo like proteins, nucleic acids, and lipids. In regenerative medicine, EVs play a significant role by influencing cellular behaviors during tissue repair and regeneration. Due to their natural function in intercellular communication, EVs represent a novel, cell-free, therapeutic tool. EVs can be further engineered to deliver therapeutic agents or modulate signaling pathways involved in repair/regeneration. Areas of interest for ExTReMe could include, but are not limited to: direct EV therapy (stem cell-isolated EVs produced under GLP conditions, and stored as off-the-shelf therapies); designer EVs (personalized to the individual patient’s needs). Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: FOR-TR-27-002
- Instrument: cooperative_agreement
Focus Areas & Funding Uses
Fields of Work
- Science research
- Healthcare
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
National Institutes of Health
Amount
Varies
Deadline
November 19, 2026
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
November 19, 2026
HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)
National Institutes of Health
Amount
Up to $375,000
Deadline
November 23, 2026
Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)
National Institutes of Health
Amount
$3,400,000 total
Deadline
November 23, 2026
Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$6,000,000 total
Deadline
November 23, 2026
Cellular Senescence Network (SenNet): SenNet Data Coordination and Integration Center (SenNet DCIC) (UM1 Clinical Trials Not Allowed)
National Institutes of Health
Amount
$3,500,000 total
Deadline
November 23, 2026
Ready to apply for Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe). Now let's win it.